Memphasys (ASX:MEM) has reached a major commercial milestone with the Therapeutic Goods Administration granting approval for its Felix System ahead of schedule, clearing the way for immediate sales and clinical deployment across Australia. …
Memphasys fast-tracks Australian market entry with early TGA approval for Felix system
February 10, 2026 Australian Biotech
Latest Video
Georgia Forrest
New Stories
-
BCEC partners with Life Sciences Queensland to launch bursary for next-gen bio innovation leaders
February 10, 2026 - - Australian Biotech -
Memphasys fast-tracks Australian market entry with early TGA approval for Felix system
February 10, 2026 - - Australian Biotech -
Algorae expands commercial footprint with new licensing deal
February 10, 2026 - - Australian Biotech -
Immutep reaches midpoint in global Phase 3 lung cancer trial
February 10, 2026 - - Australian Biotech -
Molecule2Market appoints inaugural CEO to lead next phase of growth
February 10, 2026 - - Australian Biotech -
ViiV invests in HIV-focused initiatives through Positive Action Community Grants program
February 9, 2026 - - Latest News -
A 'meeting of minds' and the risk of not being able to 'unknow' information
February 9, 2026 - - Latest News